Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Apr 2012

Thomas David L, Bartlett John G, Peters Marion G, Sherman Kenneth E, Sulkowski Mark S, Pham Paul A

Abstract excerpt

In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Guidelines as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 22173234
DOI: 10.1093/cid/cir882
PMCID: PMC3404695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.PMID 22173234Read ↗

Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.Semantic proximity Read ↗

Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.Semantic proximity Read ↗

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.Semantic proximity Read ↗

Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.Semantic proximity Read ↗

Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.Semantic proximity Read ↗

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.Semantic proximity Read ↗

Advances in the pharmaceutical care of hepatitis C/HIV co-infection.Semantic proximity Read ↗

Treatment of genotype 2 and genotype 3 hepatitis C virus (HCV) infection in human immunodeficiency virus positive patients.Semantic proximity Read ↗

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Semantic proximity Read ↗

Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.Semantic proximity Read ↗

Clinical features and therapeutic response in patients with HIV and acute HCV coinfection: a cohort studySemantic proximity Read ↗

Diagnosis, evaluation, and treatment of HIV/HCV coinfection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.